Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Marchesi, F; Salmanton-García, J; Emarah, Z; Piukovics, K; Nucci, M; López-García, A; Ráčil, Z; Farina, F; Popova, M; Zompi, S; Audisio, E; Ledoux, MP; Verga, L; Weinbergerová, B; Szotkovski, T; Da, Silva, MG; Fracchiolla, N; De, Jonge, N; Collins, G; Marchetti, M; Magliano, G; García-Vidal, C; Biernat, MM; Van, Doesum, J; Machado, M; Demirkan, F; Al-Khabori, M; Žák, P; Víšek, B; Stoma, I; Méndez, GA; Maertens, J; Khanna, N; Espigado, I; Dragonetti, G; Fianchi, L; Del, Principe, MI; Cabirta, A; Ormazabal-Vélez, I; Jaksic, O; Buquicchio, C; Bonuomo, V; Batinić, J; Omrani, AS; Lamure, S; Finizio, O; Fernández, N; Falces-Romero, I; Blennow, O; Bergantim, R; Ali, N; Win, S; Van, Praet, J; Tisi, MC; Shirinova, A; Schönlein, M; Prattes, J; Piedimonte, M; Petzer, V; Navrátil, M; Kulasekararaj, A; Jindra, P; Sramek, J; Glenthøj, A; Fazzi, R; De, Ramón-Sánchez, C; Cattaneo, C; Calbacho, M; Bahr, NC; El-Ashwah, S; Cordoba, R; Hanakova, M; Zambrotta, G; Sciumè, M; Booth, S; Rodrigues, RN; Sacchi, MV; García-Poutón, N; Martín-González, JA; Khostelidi, S; Gräfe, S; Rahimli, L; Ammatuna, E; Busca, A; Corradini, P; Hoenigl, M; Klimko, N; Koehler, P; Pagliuca, A; Passamonti, F; Cornely, OA; Pagano, L, , EPICOVIDEHA, working, group.
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA).
Haematologica. 2023; 108(1):22-33
Doi: 10.3324/haematol.2022.280847
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hönigl Martin
- Prattes Jürgen
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Adult - administration & dosage
- Follow-Up Studies - administration & dosage
- COVID-19 Testing - administration & dosage
- COVID-19 - administration & dosage
- Leukemia, Myeloid, Acute - therapy, drug therapy
- Hematology - administration & dosage